Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Assets: 2022-2025

Historic Assets for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $786.4 million.

  • NewAmsterdam Pharma Co N.V's Assets rose 79.06% to $786.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $786.4 million, marking a year-over-year increase of 79.06%. This contributed to the annual value of $864.6 million for FY2024, which is 149.10% up from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Assets of $786.4 million as of Q3 2025, which was down 3.52% from $815.1 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year Assets high stood at $864.6 million for Q4 2024, and its period low was $471,098 during Q2 2023.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Assets had a median value of $488.5 million in 2024 and averaged $556.3 million.
  • As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Assets decreased by 27.46% in 2023, and later surged by 94,718.91% in 2024.
  • NewAmsterdam Pharma Co N.V's Assets (Quarterly) stood at $478.5 million in 2022, then fell by 27.46% to $347.1 million in 2023, then surged by 149.10% to $864.6 million in 2024, then soared by 79.06% to $786.4 million in 2025.
  • Its last three reported values are $786.4 million in Q3 2025, $815.1 million for Q2 2025, and $818.4 million during Q1 2025.